-
1Academic Journal
Authors: A. V. Ignatova, A. M. Mudunov, S. О. Podvyaznikov, Yu. V. Alymov, А. В. Игнатова, А. М. Мудунов, С. О. Подвязников, Ю. В. Алымов
Source: Head and Neck Tumors (HNT); Том 10, № 2 (2020); 69-78 ; Опухоли головы и шеи; Том 10, № 2 (2020); 69-78 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2020-10-2
Subject Terms: ларотректиниб, ETV6-NTRK3, next-generation sequencing, fluorescent in situ hybridization, immunohistochemistry, polymerase chain reaction, tyrosine kinase inhibitors, entrectinib, larotrectinib, аналог секреторной карциномы молочной железы, секвенирование нового поколения, флуоресцентная гибридизация in situ, иммуногистохимия, полимеразная цепная реакция, ингибиторы тирозинкиназ, энтректиниб
File Description: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/529/426; Skálová A., Vanecek T., Sima R. et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6- NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 2010;34(5):599–608. DOI:10.1097/PAS.0b013e3181d9efcc.; Ito Y., Ishibashi K., Masaki A. et al. Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic and molecular study including 2 cases harboring ETV6-X fusion. Am J Surg Pathol 2015;39(5):602–10. DOI:10.1097/PAS.0000000000000392.; Escalante D.A., Wang H., Fundakowski C.E. Fusion proteins in head and neck neoplasms: clinical implications, genetics, and future directions for targeting. Cancer Biol Ther 2016;17(10):995–1002. DOI:10.1080/15384047.2016.1219823.; Skálová A., Vanecek T., Majewska H. et al. Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, β-catenin, EGFR, and CCND1 genes. Am J Surg Pathol 2014;38(1):23–33. DOI:10.1097/PAS.0000000000000088.; Cai Y., Cai F., Qiao H., Wang Z. The significance of the morphological and immunological characteristics in the diagnosis of parotid mammary analogue secretory carcinoma: five case reports and a review of the literature. Int J Clin Exp Pathol 2019;12(6):2233–40.; Skálová A., Vanecek T., Martinek P. et al. Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation: report of 10 cases. Am J Surg Pathol 2018;42(2):234–46. DOI:10.1097/PAS.0000000000000972.; Skálová A., Vanecek T., Simpson R.H. et al. Mammary analogue secretory carcinoma of salivary glands: molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion. Am J Surg Pathol 2016;40(1):3–13. DOI:10.1097/PAS.0000000000000537.; Stransky N., Cerami E., Schalm S. et al. The landscape of kinase fusions in cancer. Nat Commun 2014;5:4846. DOI:10.1038/ncomms5846.; Amatu A., Sartore-Bianchi A., Bencardino K. et al. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol 2019;30(Suppl 8):viii5–15. DOI:10.1093/annonc/mdz383.; Amatu A., Sartore-Bianchi A., Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 2016;1(2):e000023. DOI:10.1136/esmoopen-2015-000023.; Vaishnavi A., Le A.T., Doebele R.C. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015;5(1):25–34.; Gatalica Z., Xiu J., Swensen J., Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol 2019;32(1):147–53. DOI:10.1038/s41379-018-0118-3.; Solomon J.P., Linkov I., Rosado A. et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 2020;33(1):38–46. DOI:10.1038/s41379-019-0324-7.; Marchiò C., Scaltriti M., Ladanyi M. et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol 2019;30(9):1417–27. DOI:10.1093/annonc/mdz204.; Connor A., Perez-Ordoñez B., Shago M. et al. Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. Am J Surg Pathol 2012;36(1):27–34. DOI:10.1097/PAS.0b013e318231542a.; Suehara Y., Arcila M., Wang L. et al. Identification of KIF5B-RET and GOPCROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 2012;18(24):6599–608. DOI:10.1158/1078-0432.CCR-12-0838.; Solomon J.P., Benayed R., Hechtman J.F., Ladanyi M. Identifying patients with NTRK fusion cancer. Ann Oncol 2019;30(Suppl 8):viii16–22. DOI:10.1093/annonc/mdz384.; Drilon A., Laetsch T.W., Kummar S. et al. Efficacy of larotrectinib in TRK fusion – positive cancers in adults and children. N Engl J Med 2018;378(8):731–9. DOI:10.1056/NEJMoa1714448.; Hyman D.M., Tilburg C.M., Albert C.M. et al. Durability of response with larotrectinib in adult and pediatric patients with Trk fusion cancer. Ann Oncol 2019;30:v159–93.; Ardini E., Menichincheri M., Banfi P. et al. Entrectinib, a pan-Trk, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther 2016;15(4):628–39. DOI:10.1158/1535-7163.MCT-15-0758.; Rolfo C., De Braud F., Doebele R. et al. Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: an updated integrated analysis. J Clin Oncol 2020;38 suppl:abstr 3605.; Fischer H., Ullah M., de la Cruz C.C. et al. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro Oncol 2020;22(6):819–29. DOI:10.1093/neuonc/noaa052.; Doebele R.C., Drilon A., Paz-Ares L. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 2019;21(2):271–82. DOI:10.1016/S1470-2045(19)30691-6.; Konicek B.W., Capen A.R., Credille K.M. et al. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors. Oncotarget 2018;9(17):13796–806. DOI:10.18632/oncotarget.24488.; Drilon A., Li G., Dogan S. et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol 2016;27(5):920–26. DOI:10.1093/annonc/mdw042.; Drilon A., Wang L., Arcila M.E. et al. Broad, hybrid capture-based nextgeneration sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res 2015;21(16):3631–9. DOI:10.1158/1078-0432.CCR-14-2683.; Bishop J.A. Unmasking MASC: bringing to light the unique morphologic, immunohistochemical and genetic features of the newly recognized mammary analogue secretory carcinoma of salivary glands. Head Neck Pathol 2013;7(1):35–9. DOI:10.1007/s12105-013-0429-0.; Takeda M., Hierro C., Krauss J. et al. Entrectinib in NTRK fusion-positive mammary analogue secretory carcinoma (MASC): a phase 1/2 integrated analysis. In: Japan Society for Head and Neck Cancer 44th Annual Meeting 2020.; https://ogsh.abvpress.ru/jour/article/view/529
-
2Academic Journal
Authors: Игнатова А.В., Мудунов А.М., Подвязников С.О., Алымов Ю.В.
Source: Опухоли головы и шеи
Subject Terms: MASC-карцинома, аналог секреторной карциномы молочной железы, ETV6-NTRK3, секвенирование нового поколения, флуоресцентная гибридизация in situ, иммуногистохимия, полимеразная цепная реакция, ингибиторы тирозинкиназ, энтректиниб, ларотректиниб, mammary analogue secretory carcinoma, next-generation sequencing, fluorescent in situ hybridization, immunohistochemistry, polymerase chain reaction, tyrosine kinase inhibitors, Entrectinib, Larotrectinib
Availability: https://repository.rudn.ru/records/article/record/68717/